TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02312076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
Study: NCT01893710

Intervention type: PROCEDURE
Intervention: biopsy sampling
Description: Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.
Study: NCT02442050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: del Nido solution
Description: 1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
Study: NCT00156052

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional whole breast radiation schedule

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast radiation schedule
Study: NCT03428802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02130232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Study: NCT02442050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood-based cardioplegia
Description: An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
Study: NCT02130232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT03296098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
Study: NCT04384614

Intervention type: DIAGNOSTIC_TEST
Intervention: Test PCR
Description: Viral load (COVID+) testing by PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Test PCR
Description: Viral load (COVID+) testing by PCR

Intervention type: GENETIC
Intervention: TDR
Description: IDR and blood sampling for testing DNA Cheque

Intervention type: GENETIC
Intervention: TDR
Description: IDR and blood sampling for testing DNA Cheque

Intervention type: OTHER
Intervention: Clinical Examination
Description: COVID 19 symptoms and Physical Examination

Intervention type: OTHER
Intervention: Clinical Examination
Description: COVID 19 symptoms and Physical Examination
Study: NCT00805584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
Study: NCT03991585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Contour Regulation Facilitation (MCRF)
Description: MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Contour Regulation Facilitation (MCRF)
Description: MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
Study: NCT02160288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin-A
Description: 100 Units diluted in a 5 cc syringe at a concentration of 20U/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Dispensed in a 5 cc syringe
Study: NCT02903290

Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait

Intervention type: OTHER
Group type: OTHER
Intervention: walking track GAITRite,manual dynamometer, and treadmill
Study: NCT01916993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854 50 mg capsule
Study: NCT02561702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
Study: NCT02410018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCL 503 (uterine artery embolization)
Description: Transcatheter embolization of the uterine artery(ies) using an embolic agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCL 503 (uterine artery embolization)
Description: Transcatheter embolization of the uterine artery(ies) using an embolic agent.
Study: NCT02935998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score\>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
Study: NCT04082611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Data-Driven Clinical Recommendations
Description: Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached Data-Driven Clinical Recommendations
Description: Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
Study: NCT01820182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopies
Description: Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
Study: NCT02781623

Intervention type: PROCEDURE
Intervention: MRI
Study: NCT01924676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Study: NCT02727296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: General anesthesia with sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: General anesthesia with propofol
Study: NCT02928861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study: NCT02750514

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Study: NCT01916993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854 50 mg capsule
Study: NCT03886831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT543
Description: PRT543 will be administered orally
Study: NCT00039741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)
Description: Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
Study: NCT02750514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days
Study: NCT02142088

Intervention type: DEVICE
Group type: OTHER
Intervention: GlySure Intravascular Continuous glucose monitoring sensor
Description: Comparator device is an iSTAT device from Abbott Diagnostics
Study: NCT01823289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
Study: NCT01306292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: dose of 4.8 mL administered intravenously one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
Study: NCT01554748

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total joint arthroplasty
Study: NCT02213029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off white oral placebo tablets to match 5mg epelsiban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off white oral placebo tablets to match 5mg epelsiban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cylcen (21)® tablet
Description: White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cylcen (21)® tablet
Description: White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cylcen (21)® tablet
Description: White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
Study: NCT05809089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Description: High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Description: Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
Study: NCT02814656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
Study: NCT03431870

Intervention type: OTHER
Group type: OTHER
Intervention: Trans-esophageal echocardiography
Description: Perform a trans-esophageal echocardiography before and after anesthesia.
Study: NCT02814656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
Study: NCT01249001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aprepitant
Description: Subject will receive an oral suspension containing 125mg of Aprepitant
Study: NCT03278587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based screening program
Description: In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cataract camp program
Description: In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community health worker program
Description: In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
Study: NCT01249001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aprepitant
Description: Subject will receive an oral suspension containing 125mg of Aprepitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Subjects will receive a 125 mg Aprepitant capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Subjects will receive a 125 mg Aprepitant capsule
Study: NCT02807701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic pancreaticoduodenectomy
Description: Laparoscopic pancreaticoduodenectomy~1. dissection~2. reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreaticoduodenectomy
Description: Open pancreaticoduodenectomy
Study: NCT01120405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT04095052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methyl Folate
Description: 1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose capsule
Study: NCT02363530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl ethylcellulose (HPMC) 2% gel
Description: We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BSS
Description: Balanced Salt Solution including normal saline and glucose
Study: NCT03988023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: 4 mL injection of Ampion
Study: NCT04651530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco
Description: phacoemulsification of cataract only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phaco+ECP
Description: Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
Study: NCT00776230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: 6 mcg im. at day 0 and day 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: 6 mcg im. at day 0 and day 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: 6 mcg im. at day 0 and day 28
Study: NCT01887717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere®
Description: Intrahepatic treatment of advanced hepatocellular carcinoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard of care therapy for treatment of advanced hepatocellular carcinoma
Study: NCT04392973

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Favipiravir and Hydroxychloroquine
Description: Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily.
Study: NCT01465841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC 400 coils (Penumbra )
Description: The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.